24 November 2011 - Corporate Strategy Key to Mesoblast's Success; Chief Executive's Message to Annual General Meeting

24 November 2011 - A Year of Transformation; Chairman's Speech and Chief Executive's Presentation to AGM

22 November 2011- Positive Outcome from FDA Meeting for Type 2 Diabetes Clinical Program Using Intravenous Delivery of Mesoblast's Proprietary Adult Stem Cells

15 November 2011 - Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting

14 November 2011 – Presentation to the American Heart Association by Dr Emerson C. Perin, Texas Heart Institute

10 November 2011 - Mesoblast Reports Positive Results Using Intravenously Injected Adult Stem Cells for Type 2 Diabetes

24 October 2011 - Mesoblast Cleared to Begin First Phase 2 Clinical Trial For Eye Diseases

20 October 2011 - Licensing Executives Society (U.S.A. and Canada) 2011 Deals of Distinction™ Award for Life Sciences to Mesoblast, Cephalon Alliance

27 September 2011 – Mesoblast and Lonza Establish Strategic Global Manufacturing Alliance

5 September 2011 - Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-the-Shelf' Stem Cell Treatment for Heart Attacks

24 August 2011 - Mesoblast in Position of Considerable Strength

24 August 2011 - Mesoblast Management Presentation

24 August 2011 - Preliminary Final Report 2011

22 August 2011 - First Minimally-Invasive Procedure Performed in Mesoblast's Phase 2 Stem Cell Trial for Lumbar Disc Repair

15 August 2011 - Mesoblast’s Heart Failure Trial Selected for Presentation in Special Session of American Heart Association Annual Conference

7 July 2011 – Mesoblast Receives FDA Clearance for Phase 3 Bone Marrow Transplant Trial

29 June 2011 - United States FDA Clears Mesoblast Phase 2 Trial to Treat Degenerative Disc Disease

14 June 2011 - Mesoblast's Key Product Franchises Featured at Nomura Asia Equity Forum

9 June 2011 - Phase 2 Clinical Trial Results Show That Revascor™ Increases Blood Supply to Damaged Heart Muscle; Mesoblast expands target indications to new vascular diseases including chronic...

6 June 2011 Mesoblast to Present at Goldman Sachs 32nd Annual Global Healthcare Conference

24 May 2011 – Key Patents Granted in United States Strengthen Commercial Rights and Broaden Clinical Indications

2 May 2011 - Bloomberg media report: Teva Bets on Stem Cells, Cancer in $6.2 Billion Cephalon Bid

18 April 2011 - Mesoblast Included in S&P/ASX 200 Index

7 April 2011 – Mesoblast Update on Valeant Proposal to Cephalon

31 March 2011 – Mesoblast Statement on Valeant Proposal to Cephalon

17 March 2011 - Mesoblast CEO Named BioSpectrum Asia Person of the Year 2011

28 February 2011 – Mesoblast Half-Year Results; Strong Financial Position Underpins Company’s Ability to Deliver Increased Value from Broadened Range of Stem Cell Therapeutics

14 February 2011- Mesoblast Issues New Equity to Cephalon, Receives Further Cash Injection

9 February 2011 – Results of EGM

9 February 2011 – Chairman’s Address, CEO Presentation to EGM

31 January 2011 – Mesoblast Reports Strong Cash Position; Appendix 4C Quarterly Cash Flow Report

12 January 2011 Mesoblast – Cephalon Alliance Highlighted at JP Morgan Healthcare Conference

10 January 2011 - Interim Results from Mesoblast’s Phase 2 Heart Failure Trial Shows “Off-the-Shelf” Proprietary Adult Stem Cell Product Revascor Reduces Cardiac Events, Mortality, and Hospitalization